BruceEricSandsMD
Gastroenterology • New York, NYInflammatory Bowel Disease
Gastroenterology at Mount Sinai Doctors Faculty Practice
Dr. Sands is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Feinstein Clinical IBD Center at Mount Sinai
17 E. 102nd St., 5th Floor
New York, NY 10029Phone+1 212-241-8100Fax+1 646-537-8924- Is this information wrong?
Summary
- Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, Acting Chief of the Gastrointestinal Unit, and Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD epidemiology and includes the creation of OSCCAR (the Ocean State Crohn's & Colitis Area Registry), a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.
A leader in several major professional organizations, Dr. Sands has served as chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and Chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG).
Education & Training
Massachusetts General HospitalCertificate, Physician Leadership, Mass General Physician Organization, 2005 - 2006- Harvard School of Public HealthM.S., Epidemiology, 2001
Massachusetts General HospitalFellowship, Gastroenterology, 1990 - 1994- Harvard School of Public HealthNo degree, Clinical Effectiveness, 1993
University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990
Boston University School of MedicineClass of 1987- Boston UniversityB.A., Summa Cum Laude, 1987
Certifications & Licensure
NY State Medical License 2010 - 2026
MA State Medical License 1990 - 2011
PA State Medical License 1988 - 1990- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Selected for "Best Doctors in America" 2003-2016
- Elected as Fellow American College of Physicians (FACP), 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Join now to see all
Clinical Trials
- Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. Start of enrollment: 2013 Feb 01
- Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease Start of enrollment: 2014 Feb 01
- Evaluating a Shared Decision Making Program for Crohn's Disease Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.Laurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, Julian Panés, Stefan Schreiber, Walter Reinisch, Brian G Feagan, Silvio Danese, Andres J Yarur, Geert R D'Hae...> ;Journal of Crohn's & Colitis. 2024 Apr 13
- Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.Geert D'Haens, Taku Kobayashi, Simon Travis, Vipul Jairath, Gert De Hertogh, Bomina Park, Kim McGinnis, Isabel Redondo, Nicole G Lipitz, Theresa Hunter Gibble, Fernand...> ;Expert Review of Gastroenterology & Hepatology. 2024 Mar 21
- Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Int...Jie Shao, Marion Vetter, An Vermeulen, Brian G Feagan, Bruce E Sands, Julian Panés, Zhenhua Xu> ;Clinical Pharmacology and Therapeutics. 2024 Mar 15
- Join now to see all
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
- Correction: ACG Clinical Guideline: Management of Crohn’s Disease in AdultsGary R Lichtenstein, Bruce E Sands, Miguel D Regueiro, Kim L Isaacs, Nature
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 alleleForcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S, Proc Natl Acad Sci U S A, 1/1/1996
Lectures
- Postoperative Recurrence: How Do I Minimize Risk?Miami, FL - 1/1/2014
- Treating Ulcerative Colitis with New Biologic TherapiesSan Diego, CA - 1/1/2013
- Biologics 101San Diego, CA - 1/1/2013
- Join now to see all
Other
- The Facts About Inflammatory Bowel DiseasesSands BE, Crohn’s & Colitis Foundation of America
1/1/2011 - Quality of Care in IBDSands BE, Siegel CA, Kappelman M, Crohn’s and Colitis Foundation’s Clinical and Research Conference
Hollywood, FL - 1/10/2010 - Biologics in IBD: Do the Risks Outweigh the Benefits?Sands BE, AGA Perspectives
1/1/2010 - Join now to see all
Press Mentions
LIBERTY-UC: Maintenance Subcutaneous Infliximab Eases Moderate-to-Severe UCMay 22nd, 2023- What to Know About Infusion Therapy for IBDJanuary 10th, 2023
- Continuing Ozanimod Prevented More Relapses in Ulcerative ColitisOctober 28th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Hospital Affiliations
The Mount Sinai HospitalNew York, New York
Mount Sinai Beth IsraelNew York, New York
Mount Sinai MorningsideNew York, New York
Mount Sinai WestNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
